Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Shares Sold by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC cut its holdings in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 16.4% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,241 shares of the company’s stock after selling 834 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Immunocore were worth $126,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Assetmark Inc. increased its holdings in Immunocore by 5.3% in the 4th quarter. Assetmark Inc. now owns 32,171 shares of the company’s stock worth $949,000 after acquiring an additional 1,616 shares in the last quarter. Primecap Management Co. CA increased its stake in shares of Immunocore by 8.0% during the fourth quarter. Primecap Management Co. CA now owns 2,668,550 shares of the company’s stock worth $78,722,000 after purchasing an additional 196,530 shares in the last quarter. BIT Capital GmbH raised its position in shares of Immunocore by 182.7% during the 4th quarter. BIT Capital GmbH now owns 67,840 shares of the company’s stock worth $2,001,000 after purchasing an additional 43,840 shares during the last quarter. NEOS Investment Management LLC lifted its stake in Immunocore by 10.9% in the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company’s stock valued at $330,000 after buying an additional 1,102 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Immunocore by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 35,492 shares of the company’s stock valued at $1,047,000 after buying an additional 420 shares in the last quarter. 84.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

IMCR has been the subject of several research reports. HC Wainwright reiterated a “buy” rating and set a $100.00 price objective on shares of Immunocore in a research note on Monday, June 2nd. Needham & Company LLC reiterated a “buy” rating and set a $71.00 price target on shares of Immunocore in a research report on Thursday, April 10th. JPMorgan Chase & Co. decreased their price objective on Immunocore from $54.00 to $50.00 and set an “overweight” rating on the stock in a report on Monday, April 14th. Wall Street Zen raised shares of Immunocore from a “hold” rating to a “buy” rating in a report on Saturday, June 14th. Finally, Mizuho reduced their target price on shares of Immunocore from $38.00 to $33.00 and set a “neutral” rating for the company in a research report on Monday, April 7th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, Immunocore presently has a consensus rating of “Moderate Buy” and an average target price of $58.89.

Immunocore Stock Down 0.7%

Shares of NASDAQ:IMCR opened at $31.12 on Tuesday. Immunocore Holdings PLC Sponsored ADR has a 52-week low of $23.15 and a 52-week high of $41.54. The company has a quick ratio of 6.31, a current ratio of 6.36 and a debt-to-equity ratio of 1.03. The business has a fifty day moving average of $31.76 and a two-hundred day moving average of $30.27. The stock has a market cap of $1.56 billion, a P/E ratio of -72.37 and a beta of 0.83.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.45. Immunocore had a negative net margin of 6.48% and a negative return on equity of 5.86%. The firm had revenue of $125.13 million during the quarter, compared to analyst estimates of $108.82 million. During the same quarter in the prior year, the firm posted ($0.49) earnings per share. Immunocore’s quarterly revenue was up 33.6% on a year-over-year basis. On average, research analysts expect that Immunocore Holdings PLC Sponsored ADR will post -0.94 earnings per share for the current year.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.